Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PGSXC-L1C
- Development stage
- Unknown
- Lead developer
- PrimeGen Biotech
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
PGSXC-L1C is an investigational stem cell therapy developed by PrimeGen Biotech for the treatment of chronic liver disease. The candidate is part of PrimeGen's portfolio of pluripotent stem cell-based treatments, which utilize germ cell-derived pluripotent stem cells (gPSCs) to promote tissue regeneration. According to the company's 2021 pipeline, PGSXC-L1C was in Phase 2 development for liver indications. The therapy is designed to address the underlying pathology of chronic liver conditions by potentially restoring liver function through the differentiation of stem cells into functional hepatocytes or by providing paracrine support to existing liver tissue to stimulate endogenous repair mechanisms.
Beyond the preview
Go deeper on PGSXC-L1C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PGSXC-L1C.